Genmab — Juli 2019
-
-
Polle...Det er fair nok.
-
Enig Solsen..
-
Og tak for underbyggende link.
-
abstract in Blood journal, i can't see the full article, maybe anybody else? Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia - http://www.bloodjournal.org/content/early/2019/07/16/blood.2019000904?sso-checked=true
-
Tisotumab Vedotin innovaTV 204 Pivotal Trial Data Expected in 2020: Seattle Genetics and Genmab previously reported the completion of enrollment in the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. Topline data from the trial are expected in the first half of 2020. [ from SGEN earnings ]
-
But wouldn't they look for a partner for TV?
-
@Plimsoller Seattle Genetics is their partner.
-
Sorry. You are of course right. Thank you.
-
Q2 2019 Johnson & Johnson Earnings Call Transcript https://finance.yahoo.com/news/edited-transcript-jnj-earnings-conference-122731356.html
-
Stock... ser ud til det sker i dag..:-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind